Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Clin Res Cardiol ; 105(7): 592-600, 2016 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-26728060

RESUMEN

INTRODUCTION: Despite the ongoing debate on the role of renal sympathetic denervation (RSD) in the management of therapy-resistant hypertension, little is known about its possible effects on exercise blood pressure (BP), a known predictor for future cardiovascular events. We sought to evaluate the effect of RSD on exercise BP in a randomized, sham-controlled trial in patients with mild hypertension. METHODS AND RESULTS: Patients with therapy-resistant mild hypertension (defined by mean daytime systolic BP between 135 and 149 mmHg or mean daytime diastolic BP between 90 and 94 mmHg on 24-h ambulatory BP measurement) were randomized to either radiofrequency-based RSD or a sham procedure. Patients underwent cardiopulmonary exercise testing at baseline and after 6 months. Of the 71 patients randomized, data from cardiopulmonary exercise testing were available for 48 patients (22 in the RSD group, 26 in the sham group). After 6 months, patients undergoing RSD had a significantly lower systolic BP at maximum exercise workload compared to baseline (-14.2 ± 26.1 mmHg, p = 0.009). In contrast, no change was observed in the sham group (0.6 ± 22.9 mmHg, p = 0.45, p = 0.04 for between-group comparison). When analyzing patients with exaggerated baseline exercise BP only, the effect was even more pronounced (RSD vs. sham -29.5 ± 23.4 vs. 0.1 ± 25.3 mmHg, p = 0.008). CONCLUSION: Exercise systolic BP values in patients with mild therapy-resistant hypertension are reduced after RSD as compared to a sham-procedure.


Asunto(s)
Presión Sanguínea , Ablación por Catéter , Ejercicio Físico , Hipertensión/cirugía , Riñón/irrigación sanguínea , Arteria Renal/inervación , Arteria Renal/cirugía , Simpatectomía/métodos , Anciano , Antihipertensivos/uso terapéutico , Presión Sanguínea/efectos de los fármacos , Monitoreo Ambulatorio de la Presión Arterial , Ablación por Catéter/efectos adversos , Resistencia a Medicamentos , Prueba de Esfuerzo , Femenino , Alemania , Humanos , Hipertensión/diagnóstico , Hipertensión/fisiopatología , Masculino , Persona de Mediana Edad , Índice de Severidad de la Enfermedad , Simpatectomía/efectos adversos , Factores de Tiempo , Resultado del Tratamiento
2.
Antivir Ther ; 18(2): 193-204, 2013.
Artículo en Inglés | MEDLINE | ID: mdl-22894916

RESUMEN

BACKGROUND: Ubiquitous mitochondrial creatine kinase (uMtCK) accumulates as macroenzyme creatine kinase type 2 (macro CK2) in the serum of HIV-infected patients under a tenofovir disoproxil fumarate (TDF)-containing antiretroviral regimen. The genesis and clinical significance of this finding is unclear. METHODS: A prospective observational 5-year follow-up study was performed on those patients in which macro CK2 appearance was initially described ('TDF switch study' cohort). In addition, tenofovir (TFV), its prodrug TDF and its active, intracellular derivative TFV diphosphate (TDP) were tested in vitro for their effects on different key properties of uMtCK to clarify possible interactions of uMtCK with TFV compounds. RESULTS: In just under 5 years of continuous TDF treatment, only 4/12 (33%) patients remained macro CK2-positive, whereas 8/12 (66%) originally positive patients were macro CK2-negative at the end of follow-up. Prospective clinical follow-up data indicate that macro CK2 appearance under TDF is not associated with significant cell damage or occurrence of malignancies. A trend towards grade 1 hypophosphataemia suggests subclinical proximal tubular dysfunction in macro-CK2-positive patients, although it was not associated with a significant decrease in estimated glomerular filtration rate. In vitro, TFV, TDF and TDP did not interfere with uMtCK enzyme activity as competitive inhibitors or pseudo-substrates, but TFV and TDF stabilized the native uMtCK octameric structure in dilute solutions. CONCLUSIONS: Appearance of octameric uMtCK as macro CK2 in the serum of TDF-treated patients is suggested to result from a combination of low-level mitochondrial damage caused by subclinical renal tubular dysfunction together with possible compensatory uMtCK overexpression and a putative concomitant stabilization of uMtCK octamers by higher levels of TFV in proximal tubules.


Asunto(s)
Adenina/análogos & derivados , Fármacos Anti-VIH/farmacología , Forma Mitocondrial de la Creatina-Quinasa/metabolismo , Infecciones por VIH/metabolismo , Organofosfonatos/farmacología , Multimerización de Proteína , Adenina/farmacología , Adenina/uso terapéutico , Fármacos Anti-VIH/uso terapéutico , Catálisis/efectos de los fármacos , Forma Mitocondrial de la Creatina-Quinasa/sangre , Forma Mitocondrial de la Creatina-Quinasa/química , Estabilidad de Enzimas , Estudios de Seguimiento , Tasa de Filtración Glomerular/efectos de los fármacos , Infecciones por VIH/sangre , Infecciones por VIH/tratamiento farmacológico , Humanos , Hipofosfatemia/sangre , Organofosfonatos/uso terapéutico , Multimerización de Proteína/efectos de los fármacos , Tenofovir
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA